NAD+

Wide interest in NAD biology, with most clinical work on oral precursors rather than injected NAD+ itself.

Flushing on fast administration is consistently reported.

General profile

Class: Mitochondrial and metabolic
Evidence: Mixed or moderate evidence
Studied dose range: 50–100 mg
Frequency in protocols: 3–5× weekly
Route: Subcutaneous, slow push
Half life: Short, rapidly metabolised
Reconstitution: 5 mL bacteriostatic water per 500 mg vial
Storage: Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window

Three to five times weekly

Administration is uncomfortable and commonly causes flushing, so a slow morning push is easier to tolerate. Late dosing is frequently reported as sleep-disrupting.

Reported cycle: 4 weeks on, 4 weeks off

Most clinic protocols are short intensive blocks followed by a long gap, because tolerance to the flushing and the cost both climb.

Watch for: Chest tightness and flushing during the push, which is dose rate dependent. Slow down rather than pushing through.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

No named pair conflicts are on file for this compound. That is missing data, not clearance: with no compatibility data the default is separate syringes, and you still introduce one new compound at a time.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how NAD+ fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: Small trials of nicotinamide riboside and NMN on NAD levels, with modest functional endpoints.

Open questions: Injected NAD+ protocols are almost entirely clinic practice rather than trial data.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Sexual rehabilitation across the cystectomy care pathway: pragmatic guidance for multidisciplinary teams; a narrative review
Int J Nurs Stud Adv · 2026 · Review. Broul M, Hujova A, Liegertova M, Banyrova J, Vostry M, Dadova K.
A senescent metabolism-modulating hierarchical scaffold restores NAD+ homeostasis and redox balance for aged bone repair
Bioact Mater · 2026. Jiang J, Chen J, Wang X, Zhang X, Lv H, Wu C, Han L, Zhu Y.
Ethnopharmacological potential and mechanistic study of Platycodon grandiflorum stems and leaves and Lonicera japonica stems and leaves against acute lung injury
J Ethnopharmacol · 2026. Zhao N, Li H, Guo Y, Wu F, Wang X, Hua Y, Wei Y, Ji P, Ren J.
Electrochemical monitoring of electroactive compounds secreted by Escherichia coli during the aerobic-to-anaerobic transition
Bioelectrochemistry · 2026. Aoyagi M, Harada S, Okui F, Nagamine K.
Microbiome-driven alterations in tryptophan metabolism contribute to behavioral comorbidities in the Muc2 knockout mouse model of chronic colitis
Gut Microbes · 2026. Josephson JK, Barnett JA, Yuzbashian E, Verdugo-Meza A, Murch SJ, Wenzel TJ, Klegeris A, Sharkey KA, Gibson DL.
Effects of dinotefuran and its metabolites on the early life stage development of medaka (Oryzias latipes): In vivo and in silico studies
Toxicol Rep · 2026. Hirano M, Inoue D, Uchida M, Takahashi K, Kato K, Okobira T, Ishibashi H, Arizono K, Tominaga N.
De novo production of (-)-limonene, (-)-carveol and (-)-carvone via engineering Rhodotorula toruloides
Synth Syst Biotechnol · 2026. Dong Y, Cui S, Du B, Zhang X, Hou J, Lin X, Qin Y, Wang X, Yang X.
Thermodynamic metabolic modeling of growth and bioproduction potential of the acetogen Acetobacterium woodii with and without redox cofactor swaps
Synth Syst Biotechnol · 2026. Bauer J, von Kamp A, Pflügl S, Klamt S.
Research progress of ferroptosis in gynecological diseases
Ann Med · 2026 · Review. Chen W, Zhou W, Liu S.
The nucleus as a mechanobiological hub in muscle aging
Nucleus · 2026 · Review. Esen O, Battey E, Stroud MJ, Kirby TJ.

Search the full literature

PubMed: all indexed papers
Every indexed paper, newest first. Filter to Clinical Trial or Review in the sidebar.
PubMed: human clinical trials only
The honest test of an evidence claim. An empty result is itself an answer.
ClinicalTrials.gov registrations
Registered, ongoing and completed trials, including ones that never published.
Europe PMC full text
Often surfaces open-access full text that PubMed only abstracts.